Targeted inhibition of VEGF receptor 2: an update on ramucirumab
Author:
Publisher
Informa Healthcare
Subject
Clinical Biochemistry,Drug Discovery,Pharmacology
Link
http://www.tandfonline.com/doi/pdf/10.1517/14712598.2013.810717
Reference61 articles.
1. The Hallmarks of Cancer
2. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
3. Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
4. Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
5. Sorafenib in Advanced Hepatocellular Carcinoma
Cited by 105 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Phage Display as a Medium for Target Therapy Based Drug Discovery, Review and Update;Molecular Biotechnology;2024-06-01
2. Non–Small Cell Lung Cancer, Version 4.2024;Journal of the National Comprehensive Cancer Network;2024-05
3. Assessing patient risk, benefit, and outcomes in drug development: A decade of ramucirumab clinical trials;Cancer Medicine;2024-05
4. New Opportunities in the Systemic Treatment of Hepatocellular Carcinoma—Today and Tomorrow;International Journal of Molecular Sciences;2024-01-25
5. Prospective Observational Study of Ramucirumab Plus Docetaxel After Combined Chemoimmunotherapy in Patients With Non-Small-Cell Lung Cancer;The Oncologist;2024-01-18
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3